80 results about "Gene activity" patented technology

Bicyclonucleoside analogues which exhibit anti-AIDS activity and intermediates to produce oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability. Compounds of the following formula (1) or their pharmaceutically acceptable salts.wherein R1 represents a hydrogen atom or a protecting group for a hydroxy group, R2 represents an azido group or an optionally protected amino group or the like, B represents a purin-9-yl or a 2-oxo-1,2-dihydropyrimidin-1-yl group, which are optionally substituted with substituents selected from the group consisting of a halogen atom, an alkyl group having 1–6 carbon atoms, a hydroxy group, a mercapto group and an amino group.

Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.

The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells. Methods for identifying molecular targets for drug screening, identifying interacting gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.

The invention discloses a regulating method of a WDR63 gene in osteogenic differentiation and odontogenicdifferentiation processes of a mesenchymal stem cell. The cell is replanted by virtue of cell culture, chromatin immunoprecipitation reaction and data analysis, plasmid construction and virus infection, western blotting analysis, cell reproductive capacity determination and alkaline phosphatase and alizarin red dyeing subcutaneously of a nude mouse, and the regulating effect of the WDR63 gene in osteogenic differentiation and odontogenic differentiation processes of the mesenchymal stem cell and the effect of promoting regeneration of tooth tissues are found. By virtue of the adjusting effect of gene activity and function of the mesenchymal stem cell by trimethylation of lysine on the fourth site of histone 3, the regulating effect of the WDR63 gene in osteogenic differentiation and odontogenicdifferentiation processes of the mesenchymal stem cell and the effect of the WDR63 gene in promoting regeneration of tooth tissues, the WDR63 gene obtained probably has a promoting effect on osteogenic differentiation of stem cells from apical papilla.

The invention relates to transcription activator like effectors (TALE). The TALE can identify and bind with DNA fragments in human CCR5 gene active regions or CXCR4 gene active regions. The human CCR5 gene active regions comprise three regions and the CXCR4 gene active regions comprise two regions. The TALE binds with endonuclease so that a fusion protein TALEN is formed. Through TALEN specific loci aiming at the CCR5 or CXCR4 gene, a shearing process is carried out so that after gene regulation and control, the cell has HIV resistance.

The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Alkylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents.

The invention belongs to the field of biology engineering technology, and relates to a genetic engineering strain for producing succinic acid by utilizing glucose and an acidogenic fermentation method of the genetic engineering strain. The genetic engineering strain for producing succinic acid by utilizing glucose is named as Escherichia coli BA205 and the preservation number is registered as CCTCC No.M2011447. In the construction process, Escherichia coli which is short of lactic dehydrogenase (LDH) gene and Pyruvate formate-lyase (PFL) gene activity is mainly used as an original strain; phosphoenolpyruvate carboxylase (PPC) gene is removed by utilizing a homologous recombination technology; and phosphoenolpyruvate carboxylase and nicotinic acid phosphoribosyl transferase are excessively co-expressed; therefore the synthesis efficiency of succinic acid is greatly increased. In the fermentation method, a two-stage fermentation manner is adopted, the biomass is improved in an aerobic stage and the acidogenic fermentation is carried out in an anaerobic stage.

The present invention relates to high-throughput mammalian and medium-throughput oocyte-based electrophysiological assays for identifying human TRPML3 modulators, preferably TRPML3 enhancers. Compounds that modulate TRPML3 function in the assay are expected to affect salty taste in humans. The inventive electrophysiological assays, such as the two-electrode voltage-clamp technique, facilitate the identification of compounds which specifically modulate human TRPML3. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit TRPML3 function. Compounds that enhance or block TRPML3 channel activity should thereby modulate salty taste. In addition, these compounds may be used to regulate sodium excretion, urinary output and other biological functions relating to sodium levels. This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The inventors have identified TRPML3 as encoding a salty taste receptor in primates and humans (and likely other mammals) based on gene expression assays which have determined that TRPML3 is expressed specifically in taste bud cells and not in lingual epithelial cells, similar assays that have determined that TRPML3 is specifically expressed or enriched in the top half of taste bud cells in a subset of taste cells which do not express TRPM5 or PKD2L1, prior reports that document the expression of TRPML3 in other sensory organs such as the ear (therefore further substantiating the role of TRPML3 as a 'professional' sensory gene).

The invention provides a method for regulating chromosome genome functions by using a combined promoter, comprising the following step of: regulating and optimizing the expression of a plurality of genes in a related metabolic pathway by constructing an artificially combined type promoter sublibrary to replace a self promoter on chromosome, and therefore, the selected microorganisms can effectively generate needed products. The combined promoter comprises four artificially combined double-stranded DNA units with homologous ends, wherein the four units are assembled by a selectively marked and reformed regulating and controlling sublibrary, a reformed core promoter sublibrary and a reformed ribosome bind site library and are transformed into one or a plurality of target cells to replace the self promoters of a plurality of target chromosome genes in a specific cell pathway to cause high-expression target genes of a large amount of target cells. The method can be used for constructing a plurality of integrated bacterial strains in multiple-chromosome sites. The artificially combined type promoter can accurately, simultaneously or singly regulate and control several kinds of gene activity in cells and is suitable for metabolism optimization and metabolism control analysis in eukaryotic cells and procaryotic cells.

A method for manipulating the production of flavonoids other than anthocyanins in plants by manipulating gene activity in the flavonoid biosynthetic pathway by expressing two or more genes encoding transcription factors for flavonoid biosynthesis, compositions for use in such a method and tomato plants having altered flavonoid levels are disclosed.

Disclosed are methods for generating high-density cell microarrays. The methods generally involve forming nanocraters on a permeable membrane surface and inoculating the nanocraters with cells, proteins, or other molecules. The high-density microarrazs of the invention are useful for large-scale, high throughput phenotypic determinations of gene activities.

The invention provides a cell food for enhancing the gene activity, prepared by the following steps: 15% of red halloysite, 15% of ophicalcite, 15% of mica-schist, 10% of lapis chloriti, 10% of steatite, 15% of stalactite, 15% of mica and 5% of white mica are pulverized into micron-size particles to obtain the gene mother powder; 30% of the gene mother powder and 70% of water are mixed and steamed at high temperature, the extracted upper purified water is mixed with vinegar, glucose, xylitol and sodium cyclamate, then steamed at high temperature, and the gene wine and the gene activity enhancing liquid which is the cell food for enhancing the gene activity are extracted respectively. The gene wine and the gene activity enhancing liquid are blent to obtain the gene activity enhancing wine. The cell food can enhance the gene energy of body, supplement various microelements and mineral substances for the body, and prevent various diseases, so the cell food is beneficial for the health.

The invention discloses application of a septin gene shRNA in preparing a septin gene activity inhibitor. The method disclosed by the invention has the advantages that the growth of gliocytoma can beeffectively inhibited and no obvious damage to human normal cells such as epidermal fibroblast cells is found.

The invention discloses a method for inducing hepatic oval cells to differentiate towards bile duct cells and a special culture medium used in the method. The culture medium is added with 1 to 6 percent of fetal calf serum, 1 to 3 percent of B27 and 0.05 to 0.15 percent of penicillin-streptomycin on the basis of an RPMI1640 culture medium. The method for inducing the differentiation comprises the following steps: 1) leading RhoA mutant genes into the oval cells WB-F344 to obtain WB-F344 cells of a high-expression RhoA gene activity mutant; and 2) inoculating the WB-F344 cells of the high-expression RhoA gene activity mutant into the special culture medium where the hepatic oval cells are induced in vitro to differentiate into the bile duct cells, and culturing the WB-F344 cells at a temperature of 37 DEG C with 5 percent of CO2 to obtain the bile duct cells. The method provides a new approach to obtain the bile duct cells and has wide application prospect.

Methods of identifying agents effective as inhibitors of short heterodimer protein (SHP) and farnesoid X receptor (FXR) and promoters, cell lines and vectors used in said methods. Methods of preparing and using the agents effective as inhibitors of short heterodimer protein (SHP), including methods of using same to prevent and / or treat a condition associated with inflammatory gene activity and / or cholesterol biosynthesis in a subject. Agents effective as inhibitors of short heterodimer protein (SHP) and farnesoid X receptor (FXR) and compositions comprising same, including compositions effective in reducing inflammatory gene activity and / or cholesterol biosynthesis in a subject.

The present invention relates to a method and composition for generating a non-naturally occurring intron and its components capable of being processed into small hairpin RNA (shRNA) and / or microRNA (miRNA) molecules by skin cells and thus inducing specific gene silencing effects on skin pigment-related genes and / or aging-causing genes in the cells. The gene silencing effects so obtained are not only useful for lightening and whitening skin colors but also useful for suppressing unwanted aging gene activities in skins.

The present invention relates generally to the treatment of SCI by stimulating axon regeneration within the central nerve system. One aspect of the present invention provides methods of treating SCI with low power laser irradiation (LPLI). Another aspect of the present invention provides methods of treating SCI by modulating a gene activity to stimulate axon regeneration. In this regard, the present invention also provides compositions that modulate genes expression relating to the neuron-regeneration after SCI. Another aspect of the present invention provides methods for evaluating the effectiveness of a treatment for SCI.

The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Alkylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents.

Methods, systems, and computer readable media perform predictive modeling of gene activity. The methods may comprise obtaining the amino acid and / or nucleic acid sequence of a portion of the at least one gene from a biological sample obtained from a subject; comparing the amino acid and / or nucleic acid sequence of the portion of the at least one gene to a database of sequences for the portion of the at least one gene and for which the biological activity of the at least one gene has been evaluated; and applying a generalization of ridge regression analysis to estimate the effects of individual mutations in the at least one gene. A model is based on generalization of ridge regression (GRR) analysis to estimate the effects of individual mutations in at least one gene for the subject. At least one gene may comprise the reverse transcriptase and protease genes of an HIV vims.

Functional shRNA is produced from an expression vector prepared by selecting a two primer design in which the primers are less than about 50 nucleotides in length, annealing and extending the primers using primer extension, digesting the primer extension product and inserting the digestion product into a suitable vector. When the shRNA vectors are inserted into a cell, shRNA transcribed from the vectors modulates gene activity within the cell.

Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.

The invention provides a method for identifying transcriptional activity of an EFTUD2 promoter. The method comprises the following steps of (1) construction of an EFTUD2 promoter reporter gene recombinant vector, (2) transient transfection and (3) detection of dual luciferase reporter gene activity. The method for identifying the transcriptional activity of the EFTUD2 promoter lays a solid foundation for elucidating the expression regulation mechanism of an EFTUD2 gene, and also is conductive to further studying the relationship between the expression level of the EFTUD2 and innate immunity and a specific mechanism of differential splicing.

The invention relates to a method for obtaining a chromosomal locus for transgenesis of a multicellular eukaryotic organism, “MEO”, to a vector for transgenesis by homologous recombination of a MEO and to the use of such an vector for trans-genesis by homologous recombination of a MEO and to the transgenic MEO thus obtainable.

Methods for isolating pancreatic progenitor 1 genes are provided. The pancreatic progenitor 1 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

The invention relates to a method for preparing a genetic material born by a microvia stent. The method is characterized in that the born genetic material is dissolved at normal temperature, and a proper amount of gene activity protective agent is added; ultraphonic micro nebulization pressurizing spraying equipment is used to spray to enable the genetic material to enter the inside of a microvia and be coated on the surface of the stent. The invention adopts the microvia stent to bear the genetic material, enables the genetic material to play a role of rapid endothelialization of the genetic material in clinical applications so as to improve therapeutic effect. Firstly, the born genetic material is dissolved at normal temperature, and the proper amount of gene activity protective agent is added to ensure the genetic material to normally take effects; and secondly, by adopting the ultraphonic micro nebulization pressurizing spraying method, the genetic material is enable to successfully attach to the surface of the microvia stent, and the carrying capacity of the genetic material on the surface of each stent controllable is controllable with high repeatability precision.

The invention relates to a key protein identification method based on protein clustering characteristics and activity co-expression. The method comprises the following specific steps: describing the clustering characteristics of a protein interaction network by utilizing an edge aggregation coefficient; setting gene activity expression by setting a threshold parameter, and describing by adopting aBoolean value; defining a calculation method based on the Boolean value of gene activity expression, and calculating the score of activity co-expression by utilizing a Jaccard coefficient; finally obtaining the key comprehensive scores based on the protein clustering characteristics and the activity co-expression, outputting a sorting result, and using the protein with the high key comprehensivescore after top sorting (top N is taken as a threshold value) as a key protein. According to the key protein identification method, the influence of gene expression data noise is eliminated, and the key protein identification method is superior to a centrality measurement method and a key protein prediction method with the same input data set in the aspects of identification accuracy, specificity,sensitivity and the like.